Holen Sie sich die Stockscreener-App
26.43
0.83%
-0.22
Handel nachbörslich:
26.43
Schlusskurs vom Vortag:
$26.65
Offen:
$27.08
24-Stunden-Volumen:
633.04K
Relative Volume:
1.11
Marktkapitalisierung:
$1.47B
Einnahmen:
$2.50M
Nettoeinkommen (Verlust:
$-131.12M
KGV:
-9.2962
EPS:
-2.8431
Netto-Cashflow:
$-112.73M
1W Leistung:
+1.46%
1M Leistung:
-1.09%
6M Leistung:
-7.94%
1J Leistung:
-0.26%
1-Tages-Spanne:
$26.36
$27.49
1-Wochen-Bereich:
$24.84
$28.02
52-Wochen-Spanne:
$21.95
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
26.43 | 1.45B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-10 | Eingeleitet | Mizuho | Outperform |
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026. - Stock Titan
7,500 shares sold under a trading plan at Maze Therapeutics (MAZE) after an option exercise. - Stock Titan
An officer proposes selling 34,501 shares held by two trusts at Maze Therapeutics (Nasdaq: MAZE). - Stock Titan
Maze Therapeutics (MAZE) Valuation Turns On Early Pipeline Data Following A Recent Share Price Bounce - Simply Wall Street
Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - uk.finance.yahoo.com
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? - Yahoo Finance
Maze Therapeutics Price Target Maintained With a $46.00/Share by BTIG - Moomoo
Maze Therapeutics Initiated at Buy by Citigroup - Moomoo
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110 - Moomoo
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage - Yahoo Finance
Why is Maze Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance
BTIG Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Kidney Pill Shows Broader Promise, Lifting Rival Maze 25% - finance.biggo.com
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $64 - Moomoo
BTIG reiterates Buy rating on Maze Therapeutics, $46 price target - TradingView
Maze Therapeutics stock hits 52-week low at 22.44 USD By Investing.com - Investing.com India
Maze Therapeutics stock hits 52-week low at 22.44 USD - Investing.com
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A 166.83% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Maze Therapeutics (MAZE) Slips 1.30% to $23.91 as Shares Drift Toward Key SupportRunaway Gap - careplusvn.com
Maze Therapeutics at H.C. Wainwright conference: pipeline nears key tests By Investing.com - Investing.com Canada
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com South Africa
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria
Maze Therapeutics (MAZE) Institutional Ownership 2026 - MarketBeat
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com India
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CSBO Atul Dandekar Disposes of 6,434 Shares at $25.81-$27.12 (NASDAQ: MAZE) - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - Stock Titan
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - Stock Titan
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maze Therapeutics Inc-Aktie (MAZE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Oct 01 '26 |
Option Exercise |
10.42 |
16,141 |
168,189 |
16,141 |
| Bernstein Harold | President, R&D & CMO |
Oct 01 '26 |
Sale |
26.93 |
16,141 |
434,743 |
0 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):